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Summary Treatment of female C57BL/6 x DS-F, mice with 3'-methyl-4-dimethylaminoazobenzene (3'-Me-
DAB) neonatally resulted in the development of adenomatous nodules and glucose-6-phosphatase (G-6-Pase)
deficient foci at 8 and 6 months of age, respectively. Ovariectomy of these mice at month of age hastened the
development and increased the incidences of these lesions. Subcutaneous implantation of estradiol-17P (E2)
with ovariectomy at month of age markedly decreased the incidences of adenomatous nodules and G-6-Pase
deficient foci at 10 or 12 months of age, but subcutaneous implantation of progesterone did not reduce their
incidences. Subcutaneous implantation of E2 into ovariectomised mice at 6 months of age resulted in
significant decreases in the incidences of adenomatous nodules and G-6-Pase deficient foci at 10 months of
age, but implantation of E2 into the spleen of ovariectomised mice of the same age had no effect on their
incidences. The present results suggest that E2 suppresses the development of adenomatous nodules and
G-6-Pase deficient foci induced in the mouse liver by 3'-Me-DAB by actions on tissues other than the
liver.
The administrations of various carcinogens to young mice
before puberty induce hepatocellular tumourigenesis, male
mice being more susceptible to these carcinogens than
females (Klein, 1959; Klein & Weisburger, 1966;
Vesselinovitch & Mihailovich, 1967; Vesselinovitch, 1969;
Roe et al., 1971; Vesselinovitch et al., 1972; 1974; 1980; Rao
& Vesselinovitch, 1973; Moore et al., 1981; Yamamoto et al.,
1991). This sex difference in susceptibility is partly ascribable
to the promoting effect of testosterone secreted by the testes
after puberty (Vesselinovitch et al., 1980; Moore et al., 1981;
Kemp et al., 1989; Weghorst & Klaunig, 1989). The pro-
moting effect of testosterone on hepatocellular
tumourigenesis has been studied not only in mice but also in
rats, and has been shown to be due to indirect actions of
testosterone on tissues other than the liver, such as the
thyroid gland, not to a direct action on the liver (Toh, 1973;
Kemp et al., 1989). On the other hand, several studies
(Vesselinovitch & Mihailovich, 1967; Vesselinovitch et al.,
1980; Goldfarb & Pugh, 1990; Yamamoto et al., 1991) have
indicated that the ovaries suppress hepatocellular
tumourigenesis in mice, ovariectomy after the administration
of carcinogens shortening the latency in development of
hepatocellular tumours and increasing the incidence of
tumours. These studies suggest that the ovarian hormones,
estrogen and progesterone, suppress hepatocellular
tumourigenesis. As far as we know, however, the suppressive
effects of these two hormones on hepatocellular
tumourigenesis in mice have not been studied.
The administration of 3'-methyl-4-dimethylaminoazobenzene
(3'-Me-DAB) to neonatal female mice induces hepatocellular
tumourigenesis (Roe et al., 1971; Yamamoto et al., 1991) and
ovariectomy at 1 month of age hastens the development of
hepatocellular tumours (Yamamoto et al., 1991). In the pre-
sent study, we investigated the effects of estradiol-17P and
progesterone on the development of hepatocellular tumours
induced- by 3'-Me-DAB. We also examined whether the sup-
pressive actions of these hormones are due to direct actions
on the liver or indirect actions on tissues other than the
liver.
Materials and methods
Mice
Female C57BL/6 x DS-F1 mice bred in our laboratory were
used. These mice were kept at 25°C under controlled lighting
(12 h light/12 h darkness) and allowed free access to water
and pellet food. Mice were ovariectomised under pentobar-
bital sodium anaesthesia.
Administration ofcarcinogen
3'-Me-DAB (ICN Pharmaceuticals, Plainview, NY, USA)
was suspended in an aqueous solution of 0.7% (w/v) gelatin
at a concentration of 10 mg ml-', and 0.05 ml of the suspen-
sion was injected i.p. into mice of 10, 12, 14, 16 and 18 days
old.
Implantations ofestradiol-17I andprogesterone
Cylindrical cholesterol pellets containing 1% (w/w) estradiol-
17P (E2), hereafter called E2 pellets, were prepared, and an E2
pellet of 10 or 5 mg was implanted s.c. into the interscapular
space or the spleen. E2 pellets implanted s.c. were changed
every 4 months, but those implanted into the spleen were
not. Progesterone (about 12.5 mg) was introduced into a
silastic tube (1 cm length), and four silastic tubes were
implanted s.c. into the interscapular space. These silastic
tubes were changed every 3 months. Doses of E2 and pro-
gesterone were determined based on the results of a
preliminary experiment in which the effects of these steroids
on the uterine weight were examined.
Treatment ofmice
The study consisted of three experiments. In experiment I,
female mice treated with 3'-Me-DAB neonatally were divided
into two groups. One group was ovariectomised at 1 month
of age, and the other group was given a sham operation.
Mice (10-22 mice) from each group were killed at 4, 6, 8, 10,
12 or 16 months of age, and the liver was removed promptly.
In experiment II, female mice treated with 3'-Me-DAB were
divided into five groups. Four groups were ovariectomised at
1 month of age, and one group was given a sham operation.
The ovariectomised mice of three groups received s.c. implan-
tation of E2 pellets (10 mg), four silastic tubes, each contain-
ing about 12.5 mg of progesterone, or both E2 pellets and
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four silastic tubes with progesterone at the time of the
ovariectomy, and those of one group did not. E2 pellets and
silastic tubes with progesterone were changed every 4 and 3
months, respectively. Mice (10-20 mice) form each group
were killed at 10 or 12 months of age, and the liver and
uterus were removed promptly. In experiment III, female
mice treated with 3'-Me-DAB were ovariectomised at 1
month of age. These mice were divided into three groups,
and mice of each group received s.c. implantation of E2
pellets (10 mg), or intrasplenic implantation of E2 pellets (10
or 5 mg) at 6 months of age. Mice (22-34 mice) from each
group were killed at 10 months of age, and the liver and
uterus were removed promptly. At sacrifice of mice which
had received intrasplenic implantation of E2 pellets, adhesion
of the spleen to the abdominal wall was examined carefully,
and mice with the adhesion were excluded from the experi-
ment.
Pathological examination ofadenomatous nodules
The liver was fixed in Zamboni's solution and cut into 4-mm
thick serial strips. A thin section of each strip was prepared
and stained with hematoxylin and eosin, and all sections
(12-15 sections/the liver) were examined for adenomatous
nodules. An adenomatous nodule of hepatocellular origin in
the liver was defined with reference to previous reports
(Vesselinovitch et al., 1978; Frith et al., 1980; Lipsky et al.,
1981a) as described previously (Yamamoto et al., 1991) as a
mixture of eosinophilic, basophilic, vacuolated and foamy
hepatocyte in various proportions that compressed the adja-
cent parenchyma, but did not contain a carcinomatous lesion
with a trabecular structure. Number of adenomatous nodules
ranged from one to three per the liver.
Histochemical examination ofglucose-6-phosphatase
The right lobe of the liver was removed, and promptly frozen
in liquid nitrogen. A frozen section of the widest area was
cut at in 5-6pjm thickness on a cryostat and stained for
glucose-6-phosphatase (G-6-Pase) by the method of Wach-
stein and Meisel (1957) and examined for G-6-Pase deficient
foci. All adenomatous nodules were G-6-Pase deficient. Thus,
G-6-Pase deficient foci (Figure 1) include both preneoplastic
lesions and adenomatous nodules (Moore et al., 1981; Lipsky
et al., 1981b; Hacker et al., 1991). Number of G-6-Pase
deficient foci ranged from one to six per a section of the
widest area of the right lobe of the liver.
Labelling index
For examination of the labelling indices of adenomatous
nodules, mice were given an i.p. injection of [methyl-3H]
thymidine (2ltCi g-' body wt; 86.4 Ci mmol 1; New England
Nuclear Corp., Boston, MA, USA), and were killed 4 h later.
After fixation in Zamboni's solution, the liver was cut into
4 mm thick serial strips. Autoradiography of a thin section of
each strip was carried out by exposure for 21 days as de-
scribed previously (Terada et al., 1989). The labelling index
of adenomatous nodules with an average diameter of
3-5 mm was determined. The presence of more than five
grains on the nucleus was considered to indicate positive
labelling.
Statistical analyses
Statistical analyses were carried out by the Chi-square test or
Student's t-test. A P value of less than 0.05 was regarded as
significant.
Results
Figure 2 shows the effect of ovariectomy of 1-month-old
female mice treated with 3Y-Me-DAB neonatally on the
incidences of hepatocellular adenomatous nodules and G-6-
Pase deficient foci. Adenomatous nodules and G-6-Pase
deficient foci were first found in the liver of 16- and 12-
month-old intact females, respectively. However, in the liver
of ovariectomised females, adenomatous nodules and G-6-
Pase deficient foci were first found at 8 and 6 months of age,
respectively, and their incidences increased gradually
thereafter. The incidences of adenomatous nodules and G-6-
Pase deficient foci in ovariectomised females were
significantly higher than those in intact females of the same
age. Carcinoma was found only in one of 14 ovariectomised
females at 16 months of age, and not in intact females of the
Adenomatous nodule
100 -
50 -
50
0
0)5a):
0-i
a
14
a
20
a
18
16
1010 1010
10 12
4 6 8 10 12 16
G-6-Pase-deficient foci
10 10
4 6 8 10 12
Age (months)
14I
16
= Intact female
_ Ovariectomised female
Figure 1 G-6-Pase-deficient foci. Small arrows, preneoplastic G-
6-Pase-deficient foci. Large arrow, an adenomatous nodule.
Bar = 1 mm.
Figure 2 Effects of ovariectomy on the incidences of
adenomatous nodules and G-6-Pase-deficient foci. Female mice
were treated with 3'-Me-DAB neonatally. One group of mice was
ovariectomised at 1 month of age (-), and the other was not
(0). Mice were killed at 4, 6, 8, 10, 12 or 16 months of age.
Numbers above columns indicate numbers of mice examined
aSignificant difference from the value for intact females by the
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Figure 3 Effects of estradiol-17p and progesterone on the
incidences of adenomatous nodules and G-6-Pase-deficient foci.
Female mice were treated with 3'-Me-DAB neonatally. As
indicated, groups of mice were ovariectomised at 1 month of age,
with or without prompt implantation of E2 pellets (10 mg), four
silastic tubes (1 cm length) containing about 12.5 mg of pro-
gesterone (P), or both E2 pellets and four silastic tubes with
progesterone. Mice were killed at 10 or 12 months of age.
Numbers above columns indicate numbers of mice examined.
aSignificant difference from the value for females ovariectomised
at I month of age without implantation by the Chi-square test
(P<0.05).
same age. The above-mentioned results suggest that ovarian
hormones suppress the development of adenomatous nodules
and G-6-Pase deficient foci, so we next examined the effects
of oestrogen and progesterone on their development.
Figure 3 shows the effects of oestrogen and progesterone
on the incidences of adenomatous nodules and G-6-Pase
deficient foci in ovariectomised females at 10 or 12 months of
age. Ovariectomy at 1 month of age resulted in marked
increases in the incidences of adenomatous nodules and G-6-
Pase deficient foci at 10 or 12 months of age, and s.c.
implantation of E2 pellets (10 mg) markedly decreased their
incidences. On the other hand, s.c. implantation of four
silastic tubes, each containing about 12.5 mg of progesterone
did not decrease the incidences of adenomatous nodules and
G-6-Pase deficient foci at 10 months of age, while s.c.
implantation of both E2 pellets and four silastic tubes con-
taining progesterone reduced their incidences to the levels in
the group with implantation of E2 pellets only. Figure 4
shows the effects of oestrogen and progesterone on uterine
weight. The uterine weight of ovariectomised females with
implanted progesterone was significantly more than that of
ovariectomised females without an implant, and implantation
of progesterone plus E2 pellets significantly decreased the
uterine weight relative to that on implantation of E2 pellets
only.
The labelling indices (means ± SE) of adenomatous
nodules of 3-5 mm diameter in intact females, females
ovariectomised at 1 month of age, and females ovariec-
tomised at 1 month of age with E2 pellets implanted s.c. at 12
months of age were 1.24 ± 0.22% (n = 5), 3.10 ± 0.10%
(n = 9), and 1.01 + 0.14% (n = 6), respectively, at 15 months
of age. The labelling index of adenomatous nodules in
ovariectomised females was significantly (P<0.05) higher
than that in intact females, and was reduced significantly
(P<0.05) by implantation of E2 pellets for 3 months.
Figure 5 shows the effects of s.c. and intrasplenic implanta-
tions of E2 pellets at 6 months of age on the incidences of
adenomatous nodules and G-6-Pase deficient foci at 10
months of age. The s.c. implantation of an E2 pellet (10 mg)
significantly reduced the incidences of both adenomatous
nodules and G-6-Pase deficient foci, but the intrasplenic
implantation of an E2 pellet (10 or 5 mg) did not. The uterine
weight of ovariectomised females with E2 pellets implanted
s.c. was comparable to that of females without ovariectomy
(intact females), whereas the uterine weight of ovariectomised
females with an E2 pellet implanted into the spleen was as
low as that of ovariectomised females without an implant
(Figure 6). In the experiment shown in Figure 5, mice
received the intrasplenic implantation of E2 pellets were ex-
cluded from the experiment when adhesion of the spleen to
the abdominal wall was found at sacrifice. The uterine weight
of these mice with intrasplenic E2 pellets (10 mg) was
116.8 ± 23.0 mg (mean ± SE for eight mice), ranging from
43.2 to 238.3 mg).
Discussion
Carcinogen-induced preneoplastic and neoplastic lesions in
rat and mice show alterations in activities of various enzymes
including G-6-Pase activity (Bannasch, 1986). Hacker et al.
(1991) reported that diethylnitrosamine-induced preneoplastic
lesions in mice were G-6-Pase deficient, but adenomas show-
ed increased or decreased G-6-Pase activity and carcinomas
showed increased G-6-Pase activity. On the other hand,
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Figure 4 Effects ofestradiol-17P and progesterone on the uterine
weight. Female mice were treated as described in the legend of
Figure 3. Columns and bars represents means + SE and numbers
indicate numbers of mice examined. 'Significant difference from
the value for ovariectomised females without implantation by the
Student's t-test (P<0.05). bSignificant difference from the value
for ovariectromised females with E2 pellets by the Student's t-test
(P<0.05).
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Figure 5 Effects ofestradiol-17p implanted s.c. or into the spleen
on the incidences of adenomatous nodules and G-6-Pase-deficient
foci. Female mice were treated with 3'-Me-DAB neonatally.
These females were ovariectomised at I month of age. At 6
months of age ovariectomised females received a E2 pellet (10 mg)
s.c. or a E2 pellet (10 or 5 mg) in the spleen. All mice were killed
at 10 months of age. Numbers above columns indicate numbers
of mice examined. 'Significant difference from the value for
females ovariectomised at 1 month of age without implantation
by the Chi-square test (P<0.05).
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G-6-Pase deficient foci in various strains of mice induced by L t i15a neonatal administration of diethylnitrosamine, whereas
18 Vesselinovitch and Mihailovich (1982) reported that mest-
1111 .......................... lranol enhanced the development of mouse liver tumours
.......................... 12 a induced by the same carcinogen. Furthermore, many studies ...... ............. .. ... .. .. .. in rats showed that treatment with synthetic oestrogens fol-
B 4 34 lowing carcinogen exposure enhanced the development of
22 liver tumours (Metzler & Degen, 1987). Most synthetic oest-
rogens exert toxic effects on the rodent liver, which may
l , , , , , contribute for their effects on the development of liver
o 50 100 150 200 250 tumours. Therefore it seems necessary to use a natural oest-
Uterine weight (mg) rogen, estradiol-17,B, to examine the effects of an ovarian
hormone on hepatocellular tumourigenesis induced by
Intact female Ovex + E2 10 mg (spleen) various carcinogens in rats and mice.
Ovex female m Ovex + E2 5 mg (spleen) The s.c. implantation of E2 pellets suppressed the develop-
ment of adenomatous nodules and G-6-Pase deficient foci,
K: Ovex + E2 10 mg (s.c.) but the intrasplenic implantation of an E2 pellet did not. As
all the E2 released from the intrasplenic pellet enters the
Figure 6 Effects of estradiol-17p implanted s.c. or into the spleen portal vein, E2 cannot exert actions on tissues other than the
Dn uterine weight. Female mice were treated as described in the liver (Samuel & Eik-Nes, 1968). In contrast, E2 released from
legend of Figure 5. Columns and bars represent means + SE s.c. pellets enters the systemic circulation, and can exert
Numbers indicate numbers of mice examined. aSignificant actions on extrahepatic tissues as well as the liver. Consistent
difference from the value for ovariectomised females without with this, E2 implanted into the spleen did not increase
implantation by the Student's t-test (P<0.05). uterine weight, whereas E2 implanted s.c. increased uterine
weight to about that in intact females. In the present study,
mice which had received the intrasplenic implantation of E2
pellets were excluded from the experiment when adhesion of
the spleen to the abdominal wall was found at sacrifice, since
ipskey et at. (1981b; 1989) reported that safrole-induced or in these mice, a part of E2 secreted from E2 pellets enters the
eldrin and DDT-induced preneoplastic lesions, adenomas systemic circulation through veins of the abdominal wall.
id carcinomas were all G-6-Pase deficient. In the present The uterine weights of some of these mice with E2 pellets
udy, adenomatous nodules were G--Pase deficient, and (10 mg) were comparable to those of mice which had received
ere included in G-6-Pase deficient lesions. However, since the s.c. implantation with E2 pellets, suggesting that intras-
-6-Pase deficient lesions appeared earlier than adenomatous plenic E2 pellets could secrete E2 as long as s.c. E2 pellets.
idules both in intact and ovariectomised females treated Thus, it is unlikely that no suppressive effects of the intras-
ith 3'-Me-DAB neonatally, G-6-Pase deficient lesions except plenic implantation of E2 pellets is ascribed to the rapid
lenomatous nodules seem to be preneoplastic lesions as absorption of E2 from a pellet. Rather, the present results
ggested in hepatocellular tumourigenesis induced by the suggest that E2 suppresses hepatocellular tumourigenesis in
her carcinogens (Frith et al., 1980; Lipsky et al., 1981a; mice by its actions on tissue other than the liver. Since
81b; 1989; Moore et al., 1981; Vesselinovitch & oestrogen modulates the secretion of pituitary hormones,
ihailovich, 1983). Our previous study (Yamamoto et al., especially prolactin (Toh, 1973; Meites, 1974), the pituitary
91) using both female and male mice treated with 3'-Me- gland may be involved in the suppressive effects of oestrogen
AB neonatally, showed that adenomatous nodules on hepatocellular tumourigenesis. On the other hand, Gold-
peared earlier than carcinomas in males, and that the farb and Pugh (1990) have suggested that the promoting
arked decrease in incidence of adenomatous nodules in effect of ovariectomy on hepatocellular tumourigenesis in
males was accompanied by the marked decrease in mice may be related to weight gain, as ovariectomy results in
cidence of carcinomas. Thus, it is also likely that car- weight gain and as obesity, either strain specific or induced
nomas may arise from adenomatous nodules. by gold thioglucose, is associated with a shortening of the
E2 suppressed the development of both adenomatous latency in liver tumour development in mice (Waxler &
dules and G-6-Pase deficient foci. G-6-Pase deficient foci Tabar, 1953; Gray et al., 1960).
clude both preneoplastic lesions and adenomatous nodules In this study we found that s.c. implantation of E2
loore et al., 1981; Lipsky et al., 1981a; 1981b; 1989; decreased the incidences of adenomatous nodules and G-6-
acker et al., 1991). Thus, this result indicates that E2 sup- Pase deficient foci, but that s.c. implantation of progesterone
esses the formation of preneoplastic lesions from initiated did not. However, progesterone implanted s.c. significantly
patocytes, as well as the progression of preneoplastic increased the uterine weight of ovariectomised mice and
ions into adenomatous nodules. Furthermore, as E2 inhibited the increase in uterine weight induced by E2,
creased the labelling index of adenomatous nodules, it also indicating that when implanted s.c., it was an effective source
:ms to suppress growth of adenomatous nodules. These of progesterone (Terada et al., 1989). Thus, it is likely that
sults are consistent with a report by Goldfarb and Pugh progesterone does not affect hepatocellular tumourigenesis,
N90) that ovariectomy accelerated the growth of hepatocel- and that only oestrogen secreted by the ovaries is responsible
lar neoplasms of mice induced by diethylnitrosamine. for the suppressive effect of the ovaries on hepatocellular
Although there are no reports on the effects of E2, the tumourigenesis in mice.
Dst potent natural oestrogen, on hepatocellular We conclude from the present results that ovarian oest-
mourigenesis in mice, there are several reports on the rogen suppresses hepatocellular tumourigenesis by actions on ~ects of synthetic oestrogens on hepatocellular tissues other than the liver.
tumourigenesis in mice and rats. Studies on the effects of
synthetic oestrogens on hepatocellular tumourigenesis in mice
have, however, given discrepant results (Lee et al., 1989;
Vesselinovitch & Mihailovich, 1982). Lee et al. (1989)
reported that ethynyl estradiol suppressed the development of
We thank Mr M. Yamamoto and T. Hayashiji for animal care, Mr
M. Takatori for technical advice and Dr M. Tsuji for helpful com-
ments on the manuscript.
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